PNKP and hepatocellular carcinoma: For example, CTBP1 is listed by Cancer Resource [68], and TASP1 is also a drug target, which is used to combat novel diseases whose candidate genes are targeted by HNF4alpha splice variants in hepatocellular carcinomas [69], as well as PNKP and RAG2 [70].